# Daily Digest: Last 9 Hours: Stroke Risk From Recreational Drugs and DEA Scheduling Actions — March 08, 2026

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/daily-digest-last-9-hours-stroke-risk-from-recreational-drugs-and-dea-scheduling-actions-march-08-2026/
> **Published:** 2026-03-08T23:44:34-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:10:14-04:00
> **Clinical Summary:** A synthesis of 12 recently added cannabis articles — key themes, clinical context, and Dr. Caplan's take.

---

Last 9 Hours
 March 08, 2026 — 12 articles reviewed

This cycle was dominated by a single large Cambridge study linking recreational drug use, including cannabis, to significantly elevated stroke risk, especially in younger populations. Alongside that clinical signal, a wave of DEA scheduling actions targeting novel [synthetic opioids](https://cedclinic.com/brorphine-schedule-i-dea-four-synthetic-opioids/) rounded out a regulatory-heavy news period.

Jump to section[Cannabis, Cocaine, and Stroke Risk in Young Adults](#cannabis-cocaine-and-stroke-risk-in-youn)[Cognitive Safety of Cannabis in Older Adults](#cognitive-safety-of-cannabis-in-older-ad)[Cannabis and Alcohol Craving Reduction](#cannabis-and-alcohol-craving-reduction)[Youth Cannabis Monitoring Gaps](#youth-cannabis-monitoring-gaps)[⚖️ DEA Scheduling Wave Targets Synthetic Opioids](#dea-scheduling-wave-targets-synthetic-op)

The Cambridge stroke data deserves a permanent place in every clinician’s cannabis counseling toolkit, particularly for younger patients who assume plant-based means risk-free. Screen broadly, counsel specifically, and remember that good medicine means weighing cardiovascular signals just as seriously as we weigh the benefits.

 Browse all recent articles at [cedclinic.com/category/cannabis-news/](https://cedclinic.com/category/cannabis-news/)

Further Reading
Evidence Watch[The Brain Science Behind the Munchies – Nautilus Magazine](https://cedclinic.com/cannabis-appetite-stimulation-neuroscience/)
Evidence WatchIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).